E-viri
PDF
Recenzirano
Odprti dostop
-
Meliga, Emanuele, MD; Garcia-Garcia, Hector Manuel, MD, MSc; Valgimigli, Marco, MD, PhD; Chieffo, Alaide, MD, PhD; Biondi-Zoccai, Giuseppe, MD; Maree, Andrew O., MD; Cook, Stephen, MD; Reardon, Lindsay, MD; Moretti, Claudio, MD; De Servi, Stefano, MD; Palacios, Igor F., MD, FACC; Windecker, Stephen, MD; Colombo, Antonio, MD, FACC, FESC; van Domburg, Ron, PhD; Sheiban, Imad, MD; Serruys, Patrick W., MD, PhD, FACC, FESC
Journal of the American College of Cardiology, 06/2008, Letnik: 51, Številka: 23Journal Article
Longest Available Clinical Outcomes After Drug-Eluting Stent Implantation for Unprotected Left Main Coronary Artery Disease: The DELFT (Drug Eluting stent for LeFT main) Registry Emanuele Meliga, Hector Manuel Garcia-Garcia, Marco Valgimigli, Alaide Chieffo, Giuseppe Biondi-Zoccai, Andrew O. Maree, Stephen Cook, Lindsay Reardon, Claudio Moretti, Stefano De Servi, Igor F. Palacios, Stephen Windecker, Antonio Colombo, Ron van Domburg, Imad Sheiban, Patrick W. Serruys We investigated the long-term safety and efficacy of percutaneous coronary intervention with drug-eluting stent (DES) implantation for unprotected left main coronary artery (ULMCA) disease in a population of 358 consecutive patients analyzed in 7 European and U.S. tertiary care centers. After 3 years, major adverse cardiovascular event-free survival in the whole population was 73.5%. Cardiac death occurred in 9.2% of patients and reinfarction, target lesion revascularization, and target vessel revascularization occurred in 8.6%, 5.8%, and 14.2% of patients, respectively. Routine DES implantation in ULMCA disease seems encouraging, with favorable long-term clinical results.
